Biotech Values

[DewDiligence]

JELIS-quiz answer (?)—The clinical benefit observed in the study would presumably be more dramatic in an “enriched” dataset where patients were known to be at high risk for adverse cardiovascular events apart from their cholesterol levels. Thus, a diagnostic such as DDXS’ PLAC test (http://www.diadexus.com/products/index.php ) might enhance the commercial prospects for a drug such as AMRN’s AMR101, particularly in the primary-prevention subgroup.